MedTrace Logo

Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity

NCT02683317 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2020-07-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether docosahexaenoic acid given by enteral feeding prevent retinopathy of prematurity and/or diminish its severity in preterm infants.

Conditions

  • Retinopathy of Prematurity

Interventions

DIETARY_SUPPLEMENT

docosahexaenoic acid

Docosahexaenoic acid is a dietary supplement derived from algae.

DIETARY_SUPPLEMENT

sunflower oil

Sunflower similar to the excipient used in experimental group

Sponsors & Collaborators

  • Coordinación de Investigación en Salud, Mexico

    lead OTHER_GOV

Principal Investigators

  • Mariela Bernabe-Garcia, PhD · Instituto Mexicano del Seguro Social

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Minutes
Max Age
2 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-22
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02683317 on ClinicalTrials.gov